Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | CYNK-101 |
Trade Name | |
Synonyms | CYNK 101|CYNK101 |
Drug Descriptions |
CYNK-101 consists of CD34+ human placental-derived allogeneic NK cells engineered to express a modified version of CD16, potentially resulting in antibody-dependent cellular cytotoxicity against tumor cells (Blood 2020; 136 (Supplement 1):1). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C186655 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Aldesleukin + CYNK-101 + Pembrolizumab + Trastuzumab | Aldesleukin CYNK-101 Pembrolizumab Trastuzumab | 0 | 1 |
CYNK-101 | CYNK-101 | 0 | 0 |
CYNK-101 + Trastuzumab | CYNK-101 Trastuzumab | 0 | 0 |